What the FDA labels say about taking them together
Cobicistat and dasatinib
Cobicistat's FDA label of February 10, 2026 names dasatinib in its drug interactions section; the dasatinib labels PlainMeds reads (3) do not name cobicistat. The cobicistat label: “A decrease in the dosage or an adjustment of the dosing interval of dasatinib or nilotinib may be necessary upon coadministration with TYBOST coadministered with atazanavir or darunavir. …”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the dasatinib FDA label on DailyMed (effective November 12, 2025, Alembic Pharmaceuticals Limited).
What does the cobicistat label say about dasatinib?
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: dasatinib nilotinib vinblastine vincristine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ anticancer agents; Clinical Comment: A decrease in the dosage or an adjustment of the dosing interval of dasatinib or nilotinib may be necessary upon coadministration with TYBOST coadministered with atazanavir or darunavir. Consult the dasatinib and nilotinib prescribing information for dosing instructions. For vincristine and vinblastine, monitor for hematologic or gastrointestinal side effects.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the dasatinib label say about cobicistat?
Dasatinib's label (effective November 12, 2025) and its 2 other brand-application labels do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (DASATINIB), Alembic Pharmaceuticals Limited, effective November 12, 2025 (SPL set 645fcf26-1b2f-40c5-881b-8effe02defbd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Dasatinib | |
|---|---|---|
| Labeled for | HIV | Leukemia, lymphoma and myeloma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $26.46 per tablet 100 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once